EBOS Group Ltd (EBO) - Financial and Strategic SWOT Analysis Review

September 2020 | 53 pages | ID: E55202917FEEN
GlobalData

Abstracts

EBOS Group Ltd (EBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

EBOS Group Ltd (EBOS) is a healthcare products supplier that markets, sells, and distributes healthcare, medical and pharmaceutical products. It also markets and distributes animal care products and offers distribution, warehousing and logistics support to pharmaceutical manufacturers and medical device suppliers. The company offers products under various brands such as Symbion, Pro Pharma, Minfos, Master Pet, Vita Pet and Black Hawk, among others. EBOS serves private and public hospitals, general practitioners, aged care facilities, community centers, specialist clinics, pharmacies, professionals, consumers, pet stores, veterinary clinics and manufacturers, among others. It has presence in Australia and New Zealand. EBOS is headquartered in Docklands, Victoria, Australia.

EBOS Group Ltd Key Recent Developments

Aug 20,2020: EBOS reports a record FY20 result and significant increase in earnings
Dec 20,2019: EBOS Group: Nick Dowling appointed as an independent director
Aug 22,2019: EBOS reports solid growth in Underlying earnings as the business prepares for the next wave of growth in FY20
Aug 21,2019: EBOS Group: Retirement of Mark Waller
Feb 28,2019: EBOS Group names Stuart McLauchlan as an independent director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

EBOS Group Ltd - Key Facts
EBOS Group Ltd - Key Employees
EBOS Group Ltd - Key Employee Biographies
EBOS Group Ltd - Major Products and Services
EBOS Group Ltd - History
EBOS Group Ltd - Company Statement
EBOS Group Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
EBOS Group Ltd - Business Description
Business Segment: Animal Care
Overview
Performance
Business Segment: Healthcare
Overview
Performance
Geographical Segment: Australia
Performance
Geographical Segment: New Zealand
Performance
EBOS Group Ltd - Corporate Strategy
EBOS Group Ltd - SWOT Analysis
SWOT Analysis - Overview
EBOS Group Ltd - Strengths
EBOS Group Ltd - Weaknesses
EBOS Group Ltd - Opportunities
EBOS Group Ltd - Threats
EBOS Group Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
EBOS Group Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 20, 2020: EBOS reports a record FY20 result and significant increase in earnings
Dec 20, 2019: EBOS Group: Nick Dowling appointed as an independent director
Aug 22, 2019: EBOS reports solid growth in Underlying earnings as the business prepares for the next wave of growth in FY20
Aug 21, 2019: EBOS Group: Retirement of Mark Waller
Feb 28, 2019: EBOS Group names Stuart McLauchlan as an independent director
Feb 20, 2019: EBOS reports solid first half growth in Underlying earnings

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

EBOS Group Ltd, Key Facts
EBOS Group Ltd, Key Employees
EBOS Group Ltd, Key Employee Biographies
EBOS Group Ltd, Major Products and Services
EBOS Group Ltd, History
EBOS Group Ltd, Other Locations
EBOS Group Ltd, Subsidiaries
EBOS Group Ltd, Key Competitors
EBOS Group Ltd, Ratios based on current share price
EBOS Group Ltd, Annual Ratios
EBOS Group Ltd, Annual Ratios (Cont...1)
EBOS Group Ltd, Annual Ratios (Cont...2)
EBOS Group Ltd, Interim Ratios
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
EBOS Group Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

EBOS Group Ltd, Performance Chart (2016 - 2020)
EBOS Group Ltd, Ratio Charts
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
EBOS Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

InterMed Medical Ltd
CARE Medical Ltd
Capes Medical
Advance Diagnostics NZ Ltd